MCID: DFC004
MIFTS: 74

Deficiency Anemia

Categories: Blood diseases, Immune diseases, Respiratory diseases

Aliases & Classifications for Deficiency Anemia

Summaries for Deficiency Anemia

MedlinePlus : 42 If you have anemia, your blood does not carry enough oxygen to the rest of your body. The most common cause of anemia is not having enough iron. Your body needs iron to make hemoglobin. Hemoglobin is an iron-rich protein that gives the red color to blood. It carries oxygen from the lungs to the rest of the body. Anemia has three main causes: blood loss, lack of red blood cell production, and high rates of red blood cell destruction. Conditions that may lead to anemia include Heavy periods Pregnancy Ulcers Colon polyps or colon cancer Inherited disorders A diet that does not have enough iron, folic acid or vitamin B12 Blood disorders such as sickle cell anemia and thalassemia, or cancer Aplastic anemia, a condition that can be inherited or acquired G6PD deficiency, a metabolic disorder Anemia can make you feel tired, cold, dizzy, and irritable. You may be short of breath or have a headache. Your doctor will diagnose anemia with a physical exam and blood tests. Treatment depends on the kind of anemia you have. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Deficiency Anemia, also known as anemia, is related to iron deficiency anemia and anemia, sideroblastic, 1, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Deficiency Anemia is HBB (Hemoglobin Subunit Beta), and among its related pathways/superpathways are HIF-1 signaling pathway and Binding and Uptake of Ligands by Scavenger Receptors. The drugs Iron protein succinylate and Pyrimethamine have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and kidney, and related phenotypes are cardiovascular system and hematopoietic system

Disease Ontology : 12 A hematopoietic system disease that is characterized by a decrease in the normal number of red blood cells.

PubMed Health : 62 About anemia: Anemia (uh-NEE-me-uh) is a condition in which your blood has a lower than normal number of red blood cells. Anemia also can occur if your red blood cells don't contain enough hemoglobin (HEE-muh-glow-bin). Hemoglobin is an iron-rich protein that gives blood its red color. This protein helps red blood cells carry oxygen from the lungs to the rest of the body. If you have anemia, your body doesn't get enough oxygen-rich blood. As a result, you may feel tired or weak. You also may have other symptoms, such as shortness of breath, dizziness, or headaches. Severe or long-lasting anemia can damage your heart, brain, and other organs in your body. Very severe anemia may even cause death.

Wikipedia : 73 Anemia (also spelled anaemia) is a decrease in the total amount of red blood cells (RBCs) or hemoglobin... more...

Related Diseases for Deficiency Anemia

Diseases related to Deficiency Anemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2866)
# Related Disease Score Top Affiliating Genes
1 iron deficiency anemia 34.0 TMPRSS6 TFRC TF HBA1 HAMP G6PD
2 anemia, sideroblastic, 1 33.8 TMPRSS6 TFRC HBB HAMP GATA1
3 diamond-blackfan anemia 33.8 TFRC RPS26 RPL11 GATA1 EPO
4 iron metabolism disease 33.7 TMPRSS6 TFRC TF HBB HAMP G6PD
5 anemia, congenital dyserythropoietic, type ia 33.6 TFRC HAMP GATA1 EPO
6 iron-refractory iron deficiency anemia 33.6 TMPRSS6 EPO
7 congenital dyserythropoietic anemia 33.5 TFRC HAMP GATA1 EPO
8 hereditary spherocytosis 33.4 TFRC SPTA1 HBB GATA1 G6PD
9 diamond-blackfan anemia 1 33.3 RPL11 GATA1 FOXP3
10 heinz body anemias 33.3 LOC107133510 LOC106804612 LOC106099062 HBB HBA2 HBA1
11 microcytic anemia 33.2 TMPRSS6 TFRC TF HBA2 HBA1 HAMP
12 anemia, congenital dyserythropoietic, type ib 33.2 HAMP GATA1 G6PD
13 folic acid deficiency anemia 33.0 TFRC HAMP EPO
14 atransferrinemia 32.8 TMPRSS6 TFRC TF HAMP
15 bone marrow failure syndrome 1 32.7 TTR RPS26 FOXP3
16 glutathione peroxidase deficiency 32.7 HBB HBA2 HBA1
17 hemoglobin h disease 32.7 TFRC TF LOC106804612 HBB HBA2 HBA1
18 beta-thalassemia, dominant inclusion body type 32.7 LOC107133510 LOC106099062 HBB
19 neonatal anemia 32.5 HBA2 EPO
20 thalassemia 32.4 LOC107133510 LOC106804612 LOC106099062 HBB HBA2 HBA1
21 aceruloplasminemia 32.4 TMPRSS6 TFRC MT-ATP6 HAMP
22 hereditary elliptocytosis 32.4 SPTA1 HBB G6PD
23 fetal hemoglobin quantitative trait locus 1 32.4 LOC107133510 LOC106099062 HBB
24 beta-thalassemia 32.4 TMPRSS6 TFRC TF SPTA1 LOC107133510 LOC106099062
25 hydrops fetalis, nonimmune 32.2 HBA2 HBA1 FOXP3
26 spherocytosis, type 3 32.2 SPTA1 HBB GATA1
27 spherocytosis, type 2 32.2 SPTA1 HBB GATA1
28 porphyria cutanea tarda 32.2 TFRC TF HAMP EPO
29 hemoglobin c disease 32.1 LOC107133510 LOC106099062 HBB
30 hemoglobin zurich 32.1 LOC107133510 LOC106804612 LOC106099062 HBB HBA2
31 hemoglobin e disease 32.1 LOC107133510 LOC106099062 HBB
32 beta-thalassemia intermedia 32.1 LOC107133510 LOC106099062 HBB
33 hypochromic microcytic anemia 32.1 TMPRSS6 TFRC TF HBB HBA2 HBA1
34 hemochromatosis, type 4 32.0 TMPRSS6 TFRC HAMP
35 hemoglobinopathy 32.0 TFRC TF LOC107133510 LOC106099062 HBB HBA2
36 hemolytic anemia 32.0 TFRC TF SPTA1 LOC107133510 LOC106099062 HBB
37 iron overload in africa 31.8 TF HAMP
38 methemoglobinemia 31.8 LOC107133510 LOC106099062 HBB HBA2 HBA1 G6PD
39 hemosiderosis 31.7 TF HAMP EPO
40 thalassemia minor 31.7 LOC107133510 LOC106099062 HBB HBA2 GATA1 EPO
41 hemochromatosis, type 1 31.7 TMPRSS6 TFRC TF SPTA1 HBB HAMP
42 alpha-thalassemia 31.6 TFRC LOC107133510 LOC106804612 LOC106099062 HBB HBA2
43 cutaneous porphyria 31.6 HAMP GATA1
44 sickle cell disease 31.6 TFRC TF LOC107133510 LOC106099062 HBB HBA2
45 rare hereditary hemochromatosis 31.5 TF HAMP
46 nutritional deficiency disease 31.5 TTR TMPRSS6 TFRC TF HAMP EPO
47 malaria 31.5 TFRC SPTA1 LOC107133510 LOC106099062 HBB HBA2
48 sickle cell anemia 31.4 LOC107133510 LOC106099062 HBB HBA2 HBA1 G6PD
49 polycythemia 31.4 TFRC HBB HBA2 HAMP EPO
50 splenomegaly 31.4 LOC106804612 HBA2 HBA1 EPO

Comorbidity relations with Deficiency Anemia via Phenotypic Disease Network (PDN): (show top 50) (show all 332)


3-Hydroxyacyl-Coa Dehydrogenase Deficiency Acquired Thrombocytopenia
Active Peptic Ulcer Disease Acute Conjunctivitis
Acute Cystitis Acute Kidney Failure
Acute Leukemia Acute Maxillary Sinusitis
Acute Megakaryocytic Leukemia Acute Myocardial Infarction
Acute Pancreatitis Acute Proliferative Glomerulonephritis
Acute Vascular Insufficiency of Intestine Adjustment Disorder
Adrenal Gland Disease Agammaglobulinemia, X-Linked
Alcohol Use Disorder Alcoholic Gastritis
Alcoholic Hepatitis Alcoholic Liver Cirrhosis
Alcoholic Neuropathy Alzheimer Disease
Amyloidosis Anemia, Autoimmune Hemolytic
Anus Cancer Anxiety
Aortic Aneurysm Aortic Atherosclerosis
Aortic Valve Disease 1 Asbestosis
Ascending Colon Cancer Aspergillosis
Atrioventricular Block Atrophic Gastritis
Atypical Depressive Disorder Autonomic Nervous System Disease
Bacteremia 2 Basilar Artery Insufficiency
Benign Essential Hypertension Benign Hypertensive Renal Disease
Bladder Cancer Bleeding Disorder, Platelet-Type, 11
Blepharitis Bronchiectasis
Bronchitis Bronchopneumonia
Bullous Pemphigoid Candidiasis
Cardiac Arrest Cardiogenic Shock

Graphical network of the top 20 diseases related to Deficiency Anemia:



Diseases related to Deficiency Anemia

Symptoms & Phenotypes for Deficiency Anemia

UMLS symptoms related to Deficiency Anemia:


angina pectoris; chest pain; edema

MGI Mouse Phenotypes related to Deficiency Anemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.06 EPO FOXP3 G6PD GATA1 NRAS RPS26
2 hematopoietic system MP:0005397 9.9 EPO FOXP3 G6PD GATA1 HBA2 NRAS
3 digestive/alimentary MP:0005381 9.8 FOXP3 NRAS RPL11 SPTA1 TFRC TMPRSS6
4 integument MP:0010771 9.61 EPO FOXP3 GATA1 HBA2 NRAS SPTA1
5 liver/biliary system MP:0005370 9.23 EPO FOXP3 GATA1 NRAS RPL11 SPTA1

Drugs & Therapeutics for Deficiency Anemia

PubMed Health treatment related to Deficiency Anemia: 62

Treatment for anemia depends on the type, cause, and severity of the condition. Treatments may include dietary changes or supplements, medicines, procedures, or surgery to treat blood loss.

Drugs for Deficiency Anemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 676)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Iron protein succinylate Approved, Investigational Phase 4 250705-13-6
2
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0 4993
3
Sulfadoxine Approved, Investigational Phase 4 2447-57-6 17134
4
Amodiaquine Approved, Investigational Phase 4 86-42-0 2165
5
Artesunate Approved, Investigational Phase 4 88495-63-0 6917864 5464098
6
Quinine Approved Phase 4 130-95-0 8549 3034034
7
Zidovudine Approved Phase 4 30516-87-1 35370
8
Nevirapine Approved Phase 4 129618-40-2 4463
9
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
10
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
11
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
12
Sulfamethoxazole Approved Phase 4 723-46-6 5329
13
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
14
Halofantrine Approved Phase 4 69756-53-2 37393
15
Lactulose Approved Phase 4 4618-18-2 11333
16
Dihydroartemisinin Approved, Experimental, Investigational Phase 4 71939-50-9 6918483
17
Piperaquine Approved, Experimental, Investigational Phase 4 4085-31-8 5079497
18
Proguanil Approved Phase 4 500-92-5 4923
19
Ferrous gluconate Approved Phase 4 299-29-6
20
Cinacalcet Approved Phase 4 226256-56-0 156419
21
Lumefantrine Approved Phase 4 82186-77-4 6437380
22
Artemether Approved Phase 4 71963-77-4 119380 9796294 68911
23
Metformin Approved Phase 4 657-24-9 14219 4091
24
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
25
Doxazosin Approved Phase 4 74191-85-8 3157
26
Ramipril Approved Phase 4 87333-19-5 5362129
27
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
28
Amlodipine Approved Phase 4 88150-42-9 2162
29
Clonidine Approved Phase 4 4205-90-7 2803
30
Atenolol Approved Phase 4 29122-68-7 2249
31
Lopinavir Approved Phase 4 192725-17-0 92727
32
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
33
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
34
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
35
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
36
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
37
Desogestrel Approved Phase 4 54024-22-5 40973
38
Albendazole Approved, Vet_approved Phase 4 54965-21-8 2082
39
Tocopherol Approved, Investigational Phase 4 1406-66-2
40
Hydroxyurea Approved Phase 4 127-07-1 3657
41
Deferiprone Approved Phase 4 30652-11-0 2972
42
Deferoxamine Approved, Investigational Phase 4 70-51-9 2973
43
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
44
Lactitol Approved, Investigational Phase 4 585-86-4 157355
45
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
46
Ferric maltol Approved Phase 4 33725-54-1
47
Tranexamic Acid Approved Phase 4 1197-18-8 5526
48
Ribavirin Approved Phase 4 36791-04-5 37542
49
Deferasirox Approved, Investigational Phase 4 201530-41-8 5493381 214348
50
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821

Interventional clinical trials:

(show top 50) (show all 2913)
# Name Status NCT ID Phase Drugs
1 The Value of Iron Treatment for Postoperative Patients With Anemia: a Randomized Double Blind Controlled Trial Unknown status NCT01975272 Phase 4 Ferinject;Ferrous fumarate;Placebo for ferrous fumarate;Placebo for ferinject
2 Ferric Carboxymaltose (Ferinject®) Administered After Cardiac Surgery: (FCAACS) Effects On Correction Of Anemia And Transfusion Rates: A Prospective Randomized Controlled Trial Unknown status NCT03759964 Phase 4 Ferric carboxymaltose;Placebo
3 Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
4 Amino Acid Chelated Iron Versus Ferrous Fumarate in the Treatment of Iron Deficiency Anemia With Pregnancy: Randomized Controlled Trial Unknown status NCT03830034 Phase 4 Amino Acid chelated iron tab 15 mg;Ferrous Fumarate tab 350 mg( 115 mg elemental iron)
5 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
6 Effectiveness of Weekly and Daily Iron Supplementation for the Prevention of Iron-deficiency Anemia in Infants. Impact on Genomic Stability Unknown status NCT03359447 Phase 4 Weekly Ferrous Sulfate;Daily Ferrous Sulfate
7 Does Eradication of H-pylori in Pregnant Patients With Iron Deficiency Anemia Have an Effect on Iron Replacement Therapy? Unknown status NCT03347513 Phase 4 triple attack therapy;Ferrous(II)-glycine-sulphate complex 567.7 mg capsules
8 A Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life, and Resource Utilization of Injectafer vs. Intravenous Iron Standard of Care for the Treatment of Iron Deficiency Anemia (IDA) in an Infusion Center Setting Unknown status NCT01950247 Phase 4 Injectafer;SOC
9 Randomized, Parallel Group, Clinical Trial Comparing Intravenous Iron Sucrose Versus Oral Ferrous Sulphate in the Treatment of Perioperative Iron Deficiency in Patients With Colo-Rectal Neoplasm and Iron Deficiency Anemia. Unknown status NCT00199277 Phase 4 i.v. iron sucrose;Oral iron
10 Bovine Lactoferrin Versus Ferrous Sulphate In The Treatment Of Iron Deficiency Anemia During Pregnancy: A Randomized Controlled Trial Unknown status NCT03202615 Phase 4 F (ferrous sulphate)
11 Effektivität Der in Der Schwangerschaftsvorsorge routinemässig Angewandten Eisenprophylaxe Unknown status NCT02487719 Phase 4 Iron sulfate and Iron polymaltose for prevention of iron deficiency anemia
12 the Effectiveness of Lactoferrin in Treatment of Iron Deficiency Anemia in Children With Chronic Tonsillitis Unknown status NCT03748043 Phase 4 Lactoferrin;Ferric Hydroxide Polymaltose
13 The Effect of a Nutrient Fortified Oat Drink on Iron, Zinc, Vitamin A, and Vitamin C Status Among Filipino Children Unknown status NCT01418898 Phase 4
14 The Impact of Treatment of Anaemia With Intravenous Iron on Haematological Values for Patients After Colorectal Surgery Unknown status NCT02999217 Phase 4 Iron isomaltoside;Saline
15 Combination With Intravenous Iron Supplementation or Doubling Erythropoietin Dose for Patients With Chemotherapy-induced Anaemia Inadequately Responsive to Initial Erythropoietin Treatment Alone Unknown status NCT02731378 Phase 4 Erythropoietins (EPO);Aggressive iron dextran supplementation;Erythropoietins (EPO);Sustained iron dextran supplementation
16 An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
17 Multicenter Randomized Controlled Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion in the Treatment of Preoperative Anaemia in Colorectal Cancer Patients Unknown status NCT02243735 Phase 4 Ferrous fumarate;ferric(III)carboxymaltose
18 Effect of Mobile-Directly Observed Therapy (DOT) on Adherence to Hydroxyurea Treatment in Adult HbSS Patients at Muhimbili National Hospital (MNH) in Tanzania: a Pilot Study Unknown status NCT02844673 Phase 4 Hydroxyurea
19 Effect of Preoperative Ferric Carboxymaltose After Simultaneous Bilateral Total Knee Arthroplasty : A Randomized, Controlled, Double-Blind Trial Unknown status NCT03561506 Phase 4 Ferric carboxymaltose;0.9% Normal Saline
20 Multi-center Clinical Study of Immunosuppressants, Cyclophosphamide, And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia Unknown status NCT02838992 Phase 4 Rabbit ATG, (Genzyme);Cy;CsA
21 Treatment of Anemia in the 2nd Year of Life. Comparison of the Efficacy of Two Different Iron Preparations. Unknown status NCT00248716 Phase 4 Ferrous gluconate and iron polysaccharide complex
22 The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias Unknown status NCT02041299 Phase 4 Deferiprone;Deferoxamine
23 Different Doses of Anti-thymocyte Globin With 2.5 or 3.75mg/kg to Treat Child Severe Aplastic Anemia Unknown status NCT01997372 Phase 4 ATG
24 Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia Unknown status NCT01995331 Phase 4 cyclophosphamide,cyclosporine A
25 Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment Unknown status NCT02760940 Phase 4 oral liposomal iron
26 Efficacy and Safety of Intravenous Iron Sucrose in Patients With Hip Fracture to Prevent Perioperative Anemia Unknown status NCT01084122 Phase 4 Iron sucrose
27 Investigation of Signal Pathway Induced by Colla Corri Asini Regulating Globin Level in Beta Thalassemia Patients With Pregnancy Anemia Unknown status NCT03392298 Phase 4 Colla corii asini
28 A Multi-center Randomized, Double-blind, Placebo-controlled Study of Colla Corii Asini for the Treatment of Anemia in Pregnant Women With Thalassemia(Presenting the Syndrome of Blood Deficiency) Unknown status NCT03374111 Phase 4 Colla corii asini;a Simulate Agent of Colla corii asini granule
29 Child With Severe Aplastic Anemia (SAA) Therapy: the Injection of Umbilical Cord Derived Mesenchymal Stem Cells. Unknown status NCT02218437 Phase 4 MSC+ATG
30 Efficacy and Safety of Erythropoietin in the Treatment of Anemia in Patients With Lymphoma After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03010579 Phase 4 erythropoietin;iron supplementation
31 Phase 4 Study on the Efficacy of Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function Unknown status NCT00418119 Phase 4 erythropoietin
32 Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC Unknown status NCT01795794 Phase 4 omeprazole
33 Intravenous Iron Isomaltoside 1000 (Monofer®) Compared With Oral Iron in the Treatment of Postgastrectomy Anemia: An Open-label Randomized Controlled Trial Unknown status NCT03229954 Phase 4 iron isomaltoside (Monofer) intravenous infusion;Ferrous sulfate(Feroba-YOU) per oral
34 Effect of Postoperative Ferric Carboxymaltose After Simultaneous Bilateral Total Knee Arthroplasty : A Randomized, Controlled, Double-Blind Trial Unknown status NCT03561480 Phase 4 Ferric carboxymaltose;0.9% Normal Saline
35 The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalasemia Major Unknown status NCT02984475 Phase 4 Metformin
36 The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients Unknown status NCT00247507 Phase 4 acetylcysteine
37 A Multi-Center, Open-Label, Randomized, Parallel Group Study of the Efficacy and Safety of Ferrlecit in the Maintenance of Iron Stores and Serum Hemoglobin Concentration in Hemodialysis Patients Receiving Erythropoietin. Unknown status NCT00223938 Phase 4 Oral Iron;sodium ferric gluconate;sodium ferric gluconate
38 The Effect of Intra Venus Ferric Carboxymaltose Preoperative on Hemoglobin and Blood Transfusion Post Cardiac Surgery Unknown status NCT02939794 Phase 4 Ferinject;Placebo
39 Preoperative, Single-dose Intravenous Iron Formulation to Reduce Post-surgical Complications in Patients Undergoing Major Abdominal Surgery: a Pilot Randomised Control Trial (PIRCAS Trial - Pilot) Unknown status NCT03295851 Phase 4 Ferric carboxymaltose;Ferrous Fumarate
40 A Pilot Trial of Intravenous Iron for the Treatment of Iron Deficiency in Adult Patients With Cystic Fibrosis Unknown status NCT03632525 Phase 4 Ferric carboxymaltose
41 Effect Of Intravenous Iron Versus Placebo On Muscle Oxidative Capacity And Physical Performance In Non Anemic Premenopausal Women With Low Ferritin Levels Unknown status NCT01374776 Phase 4 Double blind, randomized, placebo controlled inter
42 Effect of Iron Supplementation on Psychomotor Development of Non-anemic Exclusively or Predominantly Breastfed Infants: Randomized, Double-blind, Placebo-controlled Trial. Unknown status NCT02242188 Phase 4 Iron
43 Effectiveness of Iron Supplementation in the Second Year of Life for Prevention of Iron Deficiency Unknown status NCT00479102 Phase 4 Ferripel-3 - iron polysaccharide complex for prevention
44 A Randomized, Double-blind, Multi-center Clinical Trial Prospectively Evaluating Iron Protein Succinylate Oral Solution in Treating Patients With Chronic Heart Failure and Iron Deficiency Unknown status NCT03344523 Phase 4 Iron protein succinylate oral solution
45 a Randomized Control Trial to Assess the Effect of Early vs Routine Iron Supplementation on Iron Store and Growth in Term Small for Gestational Age and Appropriate for Gestational Age Infants at 1 Year Unknown status NCT03171324 Phase 4 Iron Supplement
46 Parenteral Artesunate Compared to Quinine as a Cause of Late Post-treatment Anaemia in African Children With Hyperparasitaemic P. Falciparum Malaria Completed NCT02092766 Phase 4 artesunate;quinine
47 Multicenter, Prospective, Randomised, Open-label Study, Evaluating the Effect of Two Levels of Haemoglobin on Quality of Life and Speed of Progression of Renal Insufficiency on Renal Transplanted Patients With Chronic Graft Dysfunction (CGD) Completed NCT00396435 Phase 4 Neorecormon
48 A Randomized, Double-blind Comparative Study Comparing Ferric Carboxymaltose (Ferinject) and Iron Isomaltoside 1000 (Monofer) for Iron Substitution in Iron-deficiency Anemia Completed NCT02905539 Phase 4 Iron Isomaltoside 1000;Ferric Carboxymaltose
49 Prevention of Iron Deficiency in Breastfed Infants Completed NCT01444261 Phase 4
50 Safety of Cotrimoxazole in HIV- and HAART-exposed Infants in Botswana Completed NCT01086878 Phase 4 cotrimoxazole

Search NIH Clinical Center for Deficiency Anemia

Inferred drug relations via UMLS 70 / NDF-RT 51 :


darbepoetin alfa
Epoetin Alfa
Nandrolone
nandrolone decanoate
nandrolone phenpropionate
Oxymetholone
Sodium Ascorbate

Cochrane evidence based reviews: anemia

Genetic Tests for Deficiency Anemia

Genetic tests related to Deficiency Anemia:

# Genetic test Affiliating Genes
1 Anemia 29

Anatomical Context for Deficiency Anemia

MalaCards organs/tissues related to Deficiency Anemia:

40
Bone Marrow, Bone, Kidney, Liver, Heart, Myeloid, Breast

Publications for Deficiency Anemia

Articles related to Deficiency Anemia:

(show top 50) (show all 35640)
# Title Authors PMID Year
1
Anemia predicts poor outcomes of COVID-19 in hospitalized patients: a prospective study in Iran. 61 42
33568084 2021
2
Sex-related associations among anemia, body mass index, and kidney function in Koreans: A cross-sectional study with propensity analysis. 61 42
33530196 2021
3
Whole-genome sequencing of patients with rare diseases in a national health system. 6
32581362 2020
4
Prevalence of anaemia and compliance to weekly iron-folic acid supplementation programme amongst adolescents in selected schools of urban Puducherry, India. 42
33642324 2021
5
Ribosomal protein S19 binds to its own mRNA with reduced affinity in Diamond-Blackfan anemia. 54 61
20395159 2010
6
Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. 54 61
20406921 2010
7
Evidence of receptor-mediated elimination of erythropoietin by analysis of erythropoietin receptor mRNA expression in bone marrow and erythropoietin clearance during anemia. 54 61
20103588 2010
8
Polyarthritis and anemia in a hemodialysis patient: systemic lupus erythematosus following treatment with interferon alpha. 54 61
20353741 2010
9
Low-density lipoprotein apheresis decreases ferritin, transferrin and vitamin B12, which may cause anemia in serially treated patients. 61 54
20438534 2010
10
Hematological predictors of increased severe anemia in Kenyan children coinfected with Plasmodium falciparum and HIV-1. 61 54
20196168 2010
11
Iron regulatory hormone hepcidin decreases in chronic heart failure patients with anemia. 61 54
20019408 2010
12
The first case of a class I glucose-6-phosphate dehydrogenase deficiency, G6PD Santiago de Cuba (1339 G > A), in a Chinese population as found in a survey for G6PD deficiency in northeastern and central China. 54 61
20200584 2010
13
[Soluble tranferrin receptor in the biological diagnosis of iron deficiency. Report of 24 cases]. 54 61
20209848 2009
14
Hemolytic anemia after zopiclone overdose. 61 54
19821637 2009
15
Hemochromatosis gene mutations and treatment of anemia in patients on hemodialysis. 61 54
19732172 2009
16
[Management of anemia and bone marrow hypoplasia in the treatment of myeloid leukemia]. 54 61
19860200 2009
17
Serum transferrin receptors: Distribution and diagnostic performance in pre-school children. 54 61
19394251 2009
18
MIF (macrophage migration inhibitory factor) promoter polymorphisms and susceptibility to severe malarial anemia. 54 61
19591577 2009
19
Naturally acquired hemozoin by monocytes promotes suppression of RANTES in children with malarial anemia through an IL-10-dependent mechanism. 61 54
19427395 2009
20
[Anemia in hospitalized patients with cirrhosis: prevalence, clinical relevance and predictive factors]. 54 61
19663083 2009
21
Time course of anemia during six months follow up following intensive care discharge and factors associated with impaired recovery of erythropoiesis. 61 54
19384207 2009
22
Causes and consequences of inflammation on anemia management in hemodialysis patients. 54 61
19432697 2009
23
Role of interleukin-6 in the anemia of chronic disease. 54 61
18336871 2009
24
Novel models of cancer-related anemia in mice inoculated with IL-6-producing tumor cells. 61 54
19265263 2009
25
Current controversies in the management of the anemia of prematurity. 61 54
19167579 2009
26
[Density-specific distribution of erythrocytes in different types of anemia]. 54 61
19253711 2009
27
[Molecular factors of angiogenesis in renal tissue of patients with chronic glomerulonephritis: association with nephrosclerosis and anemia]. 54 61
19799194 2009
28
Severe sirolimus-related inflammatory state anemia in an HIV+ liver transplant patient with calcineurin inhibitor renal insufficiency: a case report. 61 54
19100499 2008
29
Anemia of chronic disease and defective erythropoietin production in patients with celiac disease. 61 54
18815191 2008
30
[Expression of erythropoietin receptor in leukemia cells and relation of erythropoietin level with leukemic anemia]. 54 61
19099624 2008
31
The role of oxidative stress in hemolytic anemia. 54 61
18991647 2008
32
First synthesis of N-[(aziridin-2-yl)methyl]benzimidazolequinone and analysis of toxicity towards normal and Fanconi anemia cells. 54 61
18997962 2008
33
The anemia of ageing is not associated with increased plasma hepcidin levels. 54 61
18676162 2008
34
Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis. 54 61
18837771 2008
35
Is obesity associated with anemia of chronic disease? A population-based study. 54 61
18719644 2008
36
Anemia and cerebral outcomes: many questions, fewer answers. 54 61
18806052 2008
37
Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. 61 54
18547996 2008
38
Long-term treatment of anemia with recombinant human erythropoietin in familial amyloidosis TTR V30M. 61 54
18925459 2008
39
Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia. 61 54
18758412 2008
40
C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. 54 61
18760763 2008
41
Low serum levels of prohepcidin, but not hepcidin-25, are related to anemia in familial amyloidosis TTR V30M. 61 54
18544472 2008
42
Phlebotomies or erythropoietin injections allow mobilization of iron stores in a mouse model mimicking intensive care anemia. 54 61
18664788 2008
43
Anemia associated with impaired erythropoietin secretion after allogeneic stem cell transplantation: incidence, risk factors, and response to treatment. 54 61
18640571 2008
44
Relationship between inflammatory cytokines and cardiorenal anemia syndrome: treatment with recombinant human erythropoietin (rhepo). 61 54
18923748 2008
45
Anemia in monkey collagen-induced arthritis is correlated with serum IL-6, but not TNFalpha. 54 61
18309490 2008
46
Characterization of the N-glycosylation phenotype of erythrocyte membrane proteins in congenital dyserythropoietic anemia type II (CDA II/HEMPAS). 61 54
18166993 2008
47
Anemia and iron status in young fertile non-professional female athletes. 54 61
18092176 2008
48
Similar cytokine responses and degrees of anemia in patients with Plasmodium falciparum and Plasmodium vivax infections in the Brazilian Amazon region. 61 54
18256207 2008
49
[Anemia and lung cancer]. 61 54
18589288 2008
50
Reduced immune complex binding capacity and increased complement susceptibility of red cells from children with severe malaria-associated anemia. 61 54
18317566 2008

Variations for Deficiency Anemia

ClinVar genetic disease variations for Deficiency Anemia:

6 (show all 16)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 overlap with 6 genes NG_000007.3:g.63632_71046del Deletion Pathogenic 15061 GRCh37: 11:5247800-5255214
GRCh38: 11:5226570-5233984
2 HBA1 , LOC106804612 , HBA2 NM_000517.6(HBA2):c.410T>C (p.Leu137Pro) SNV Pathogenic 15655 rs41469945 GRCh37: 16:223580-223580
GRCh38: 16:173581-173581
3 FOXP3 NM_014009.3(FOXP3):c.1190G>A (p.Arg397Gln) SNV Pathogenic 379222 rs1057520529 GRCh37: X:49107901-49107901
GRCh38: X:49251440-49251440
4 TTR NM_000371.4(TTR):c.424G>A (p.Val142Ile) SNV Pathogenic 13426 rs76992529 GRCh37: 18:29178618-29178618
GRCh38: 18:31598655-31598655
5 LOC106099062 , HBB , LOC107133510 NM_000518.5(HBB):c.79G>A (p.Glu27Lys) SNV Pathogenic 15161 rs33950507 GRCh37: 11:5248173-5248173
GRCh38: 11:5226943-5226943
6 LOC106099062 , HBB , LOC107133510 NM_000518.5(HBB):c.20A>T (p.Glu7Val) SNV Pathogenic 15333 rs334 GRCh37: 11:5248232-5248232
GRCh38: 11:5227002-5227002
7 NRAS NM_002524.5(NRAS):c.176C>A (p.Ala59Asp) SNV Likely pathogenic 812886 rs1570874751 GRCh37: 1:115256535-115256535
GRCh38: 1:114713914-114713914
8 overlap with 171 genes Deletion Likely pathogenic 812956 GRCh37: 11:114433313-131230466
GRCh38:
9 GATA1 NM_002049.4(GATA1):c.680C>T (p.Ala227Val) SNV Likely pathogenic 812972 rs1602220307 GRCh37: X:48650811-48650811
GRCh38: X:48792404-48792404
10 MT-ATP6 , MT-ATP8 NC_012920.1:m.8570T>C SNV Likely pathogenic 869162 GRCh37: MT:8570-8570
GRCh38: MT:8570-8570
11 RPL11 NM_000975.5(RPL11):c.142_143dup (p.Val49fs) Duplication Likely pathogenic 812883 rs1570566714 GRCh37: 1:24019231-24019232
GRCh38: 1:23692741-23692742
12 RPS26 NM_001029.5(RPS26):c.312+2T>A SNV Likely pathogenic 812897 rs1593023809 GRCh37: 12:56437279-56437279
GRCh38: 12:56043495-56043495
13 SPTA1 NM_003126.4(SPTA1):c.2464+1G>A SNV Likely pathogenic 812890 rs774632615 GRCh37: 1:158632491-158632491
GRCh38: 1:158662701-158662701
14 ANK1 NM_000037.4(ANK1):c.1948A>G (p.Met650Val) SNV Uncertain significance 373944 rs1057518790 GRCh37: 8:41566346-41566346
GRCh38: 8:41708828-41708828
15 GATA2 NM_001145661.2(GATA2):c.971A>G (p.Lys324Arg) SNV Uncertain significance 523417 rs1480450110 GRCh37: 3:128202749-128202749
GRCh38: 3:128483906-128483906
16 YARS1 NM_003680.3:c.611A>C SNV Uncertain significance 986742 GRCh37: 1:33256836-33256836
GRCh38: 1:32791235-32791235

Expression for Deficiency Anemia

Search GEO for disease gene expression data for Deficiency Anemia.

Pathways for Deficiency Anemia

GO Terms for Deficiency Anemia

Cellular components related to Deficiency Anemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.02 TTR TMPRSS6 TFRC TF HBB HBA2
2 extracellular exosome GO:0070062 10.02 TTR TFRC TF RPS26 RPL11 NRAS
3 cytosolic small ribosomal subunit GO:0022627 9.58 RPS26 HBA2 HBA1
4 HFE-transferrin receptor complex GO:1990712 9.43 TFRC TF
5 endocytic vesicle lumen GO:0071682 9.43 HBB HBA2 HBA1
6 hemoglobin complex GO:0005833 9.33 HBB HBA2 HBA1
7 haptoglobin-hemoglobin complex GO:0031838 9.13 HBB HBA2 HBA1
8 blood microparticle GO:0072562 9.02 TFRC TF HBB HBA2 HBA1

Biological processes related to Deficiency Anemia according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 receptor-mediated endocytosis GO:0006898 9.67 TFRC HBB HBA2 HBA1
2 cellular oxidant detoxification GO:0098869 9.65 HBB HBA2 HBA1
3 response to hydrogen peroxide GO:0042542 9.61 HBB HBA2 HBA1
4 positive regulation of cell death GO:0010942 9.58 HBB HBA2 HBA1
5 response to vitamin A GO:0033189 9.55 HAMP EPO
6 iron ion transport GO:0006826 9.54 TFRC TF
7 positive regulation of bone resorption GO:0045780 9.52 TFRC TF
8 response to hyperoxia GO:0055093 9.51 MT-ATP6 EPO
9 bicarbonate transport GO:0015701 9.5 HBB HBA2 HBA1
10 erythrocyte maturation GO:0043249 9.49 G6PD EPO
11 myeloid cell homeostasis GO:0002262 9.46 HAMP FOXP3
12 iron ion homeostasis GO:0055072 9.43 TMPRSS6 TF HAMP
13 hydrogen peroxide catabolic process GO:0042744 9.33 HBB HBA2 HBA1
14 oxygen transport GO:0015671 9.13 HBB HBA2 HBA1
15 cellular iron ion homeostasis GO:0006879 8.92 TMPRSS6 TFRC TF HAMP

Molecular functions related to Deficiency Anemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.54 TTR HAMP EPO
2 peroxidase activity GO:0004601 9.5 HBB HBA2 HBA1
3 oxygen binding GO:0019825 9.43 HBB HBA2 HBA1
4 oxygen carrier activity GO:0005344 9.33 HBB HBA2 HBA1
5 organic acid binding GO:0043177 9.13 HBB HBA2 HBA1
6 haptoglobin binding GO:0031720 8.8 HBB HBA2 HBA1

Sources for Deficiency Anemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53